Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis Ketek CAP Resistance Claim Needs Larger Trials, Advisory Cmte. Says

Executive Summary

Aventis Ketek (telithromycin) needs additional studies in more patients with penicillin- and erythromycin-resistant Streptococcus pneumoniae, FDA's Anti-Infectives Advisory Committee said April 26.

You may also be interested in...



Aventis Ketek July Launch Will Highlight Targeted Antibacterial Activity

Aventis' promotional message for Ketek will center on the antibiotic's ability to specifically target all pathogens commonly associated with respiratory tract infections without affecting other bacterial strains

Aventis Ketek July Launch Will Highlight Targeted Antibacterial Activity

Aventis' promotional message for Ketek will center on the antibiotic's ability to specifically target all pathogens commonly associated with respiratory tract infections without affecting other bacterial strains

Aventis Plans To Launch Genasense, Ketek and Apidra In 2004

The launch of Genasense will be a key step in Aventis' plans to build its oncology franchise, Chief Operating Officer Richard Markham said Jan. 13 during the J.P. Morgan health care conference in San Francisco

Related Content

UsernamePublicRestriction

Register

PS037730

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel